Pandion Therapeutics Inc Revenue Growth Rates (PAND), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Pandion Therapeutics Inc   (NASDAQ: PAND)
 

PAND's Revenue Growth by Quarter and Year

Pandion Therapeutics Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

PAND Revenue (in millions $) FY 2020 FY 2019 FY 2018 FY 2017
4th Quarter December 2.19
3rd Quarter September 2.63
2nd Quarter June 1.96
1st Quarter March 0.00
FY 6.78





PAND Revenue fourth quarter 2020 Y/Y Growth Comment
Pandion Therapeutics Inc achieved in the fourth quarter 2020, above Company average Revenue surge of 125.88% year on year, to $ 2.19 millions.

Looking into fourth quarter 2020 results within Major Pharmaceutical Preparations industry 243 other companies have achieved higher Revenue growth. While Pandion Therapeutics Inc ' s Revenue doubling of 125.88% ranks overall at the positon no. 4039 in the fourth quarter 2020.


PAND Revenue ( Y/Y Growth %) 2020
 2019 2018 2017
4th Quarter December 125.88 % - - -
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY   599.07 % - - -

Financial Statements
Pandion Therapeutics Inc 's fourth quarter 2020 Revenue $ 2.19 millions PAND's Income Statement
Pandion Therapeutics Inc 's fourth quarter 2019 Revenue $ 0.97 millions Quarterly PAND's Income Statement


PAND Revenue (Quarter on Quarter Growth %)

 2020
 2019 2018 2017
4th Quarter December -16.69 % - - -
3rd Quarter September 34.18 % - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY (Year on Year)   599.07 % - - -


Back to PAND Growth rate Comparisons >> Back to PAND Growth rate Comparisons >>


Revenue fourth quarter 2020 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #244
Healthcare Sector #617
Overall #4039

Revenue Y/Y Growth Statistics
High Average Low
34.63 % -27.38 % -100 %
(Sep 30 2020)   (Mar 31 2020)
Revenue fourth quarter 2020 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #244
Healthcare Sector #617
Overall #4039
Revenue Y/Y Growth Statistics
High Average Low
34.63 % -27.38 % -100 %
(Sep 30 2020)   (Mar 31 2020)

Revenue by Quarter for the Fiscal Years 2017, 2018, 2019, 2020

Pandion Therapeutics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
34.63 % -27.38 % -100 %
(Sep 30 2020)  


PAND's IV. Quarter Q/Q Revenue Comment
In the IV. Quarter 2020 Pandion Therapeutics Inc disclosed fall in Revenue from the third quarter by -16.69% to $ 2.19 millions, from $ 2.63 millions achived in the previous reporting period.

Within Major Pharmaceutical Preparations industry 243 other companies have achieved higher Revenue quarter on quarter growth. While Pandion Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 4039.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #244
Healthcare Sector #617
Overall #4039
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #244
Healthcare Sector #617
Overall #4039
Revenue Q/Q Growth Statistics
High Average Low
34.63 % -27.38 % -100 %
(Sep 30 2020)  


PAND's IV. Quarter Q/Q Revenue Comment
In the IV. Quarter 2020 Pandion Therapeutics Inc disclosed fall in Revenue from the third quarter by -16.69% to $ 2.19 millions, from $ 2.63 millions achived in the previous reporting period.

Within Major Pharmaceutical Preparations industry 243 other companies have achieved higher Revenue quarter on quarter growth. While Pandion Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 4039.


Pandion Therapeutics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Dec 31 2020)		 12 Months Ending
(Sep 30 2020)		 12 Months Ending
(Jun 30 2020)		 12 Months Ending
 12 Months Ending
Cumulative Revenue 12 Months Ending $ 0.00 $ 0.00 $ 1.96 $ 0.00 $ 0.00
Y / Y Revenue Growth (TTM) - - - - -
Year on Year Revenue Growth Overall Ranking # # # # #
Seqeuential Revenue Change (TTM) - - - - -
Seq. Revenue Growth (TTM) Overall Ranking # # # # #


Cumulative Revenue growth Comment
In the Dec 31 2020 period, Pandion Therapeutics Inc 's cumulative trailing twelve month Revenue remained unchanged compare to the same period a year ago.

Pandion Therapeutics Inc achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
 0 %
0 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Revenue growth Comment
In the Dec 31 2020 period, Pandion Therapeutics Inc 's cumulative trailing twelve month Revenue remained unchanged compare to the same period a year ago.

Pandion Therapeutics Inc achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
PAND's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue fall for the quarter ending Dec 31 2020 within Healthcare SectorY/Y Change %Revenue for the quarter ending Dec 31 2020
Vapotherm Inc 214.43%$ 214.427 millions
Bioadaptives Inc 214.32%$ 214.322 millions
Ascendis Pharma A185.99%$ 185.993 millions
Precipio inc 182.12%$ 182.122 millions
Lannett Company Inc170.84%$ 170.835 millions
Old Ayala Inc 169.89%$ 169.892 millions
Agape Atp Corporation167.71%$ 167.705 millions
Reflect Scientific Inc165.79%$ 165.789 millions
Alpha Pro Tech Ltd 165.77%$ 165.766 millions
Sunshine Biopharma Inc 165.38%$ 165.375 millions
Collplant Biotechnologies Ltd164.75%$ 164.754 millions
Ethema Health Corporation 162.82%$ 162.819 millions
Biotricity Inc 162.18%$ 162.177 millions
Ligand Pharmaceuticals Incorporated159.19%$ 159.193 millions
Avalo Therapeutics Inc 157.61%$ 157.605 millions
Ultragenyx Pharmaceutical Inc 157.19%$ 157.191 millions
T2 Biosystems Inc 153.76%$ 153.763 millions
Retractable Technologies Inc153.34%$ 153.343 millions
Myomo Inc 149.23%$ 149.226 millions
Ontrak Inc 148.78%$ 148.775 millions
Teladoc Health Inc 144.95%$ 144.951 millions
Polarityte Inc 144.88%$ 144.884 millions
Outset Medical Inc 143.43%$ 143.430 millions
Immunitybio inc 133.33%$ 133.333 millions
Adapthealth Corp 133.00%$ 132.999 millions
Seres Therapeutics Inc 130.44%$ 130.438 millions
Interpace Biosciences Inc 128.83%$ 128.826 millions
Alnylam Pharmaceuticals Inc 128.18%$ 128.180 millions
Protagonist Therapeutics inc 127.09%$ 127.090 millions
Halozyme Therapeutics Inc 126.78%$ 126.783 millions


About Pandion Therapeutics Inc Revenue Growth Rates (PAND), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: the company’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.